Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Results of a meta-analysis indicate that moderate doses of inhaled corticosteroids do not have any clinically relevant advantage over low doses in children…
NEW YORK (Reuters Health) – The mineralocorticoid receptor blocker eplerenone has advantages over spironolactone in the treatment of chronic heart failure (CHF), a Japanese team reports. In particular,…
NEW YORK (Reuters Health) – While elevated levels of anticardiolipin antibodies are associated with preeclampsia, measuring levels of anticardiolipin antibodies cannot be used to predict risk of preeclampsia…
NEW YORK (Reuters Health) – Contrary to growing concerns, the incidence of coronary artery aneurysms after implantation of drug-eluting stents is low, and when an aneurysm does occur…
NEW YORK (Reuters Health) – In the short term, cryoablation for atrioventricular nodal reentrant tachycardia (AVNRT) is as effective as radiofrequency catheter ablation, but 6-month recurrence rates are…
NEW YORK (Reuters Health) – Urologists from China report that the alpha-adrenergic receptor antagonist tamsulosin is a good first-line drug for outpatient medical expulsive therapy (MET) in patients…
NEW YORK (Reuters Health) – Among very low birth weight (VLBW) preterm infants, those treated with oral ibuprofen for patent ductus arteriosus have higher rates of closure than…
NEW YORK (Reuters Health) – Over time, cervical intraepithelial neoplasia (CIN) grade 2 eventually resolves spontaneously in about two-thirds of adolescent and young adult women, according to findings…
NEW YORK (Reuters Health) – The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who…
NEW YORK (Reuters Health) – Anemia that develops in hepatitis C virus (HCV) patients during treatment with peginterferon-alfa and ribavirin (PEG-IFN/RBV) may be a good sign, new research…
